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Abstract
Background: Allergic rhinitis (AR) and asthma are inflammatory conditions of the airways that
often occur concomitantly. This global survey was undertaken to understand patient perspectives
regarding symptoms, treatments, and the impact on their well-being of comorbid AR and asthma.
Methods: Survey participants were adults with asthma (n = 813) and parents of children with
asthma (n = 806) from four countries each in the Asia-Pacific region and Europe. Patients included
in the survey also had self-reported, concomitant AR symptoms. Patients and parents were
recruited by telephone interview or by direct interview.
Results: Most patients (73%) had pre-existing symptoms of AR when their asthma was first
diagnosed. Shortness of breath (21%) was the most troublesome symptom for adults, and wheezing
(17%) and coughing (17%) the most troublesome for children. Patients used different medications
for treating asthma (most commonly short-acting β-agonists and inhaled corticosteroids) and for
treating AR (most commonly oral antihistamines). The concomitant presence of AR and asthma
disrupted the ability to get a good night's sleep (79%), to participate in leisure and sports activities
(75%), to concentrate at work or school (69% of adults, 73% of children), and to enjoy social
activities (57% of adults, 51% of children). Most patients (79%) reported worsening asthma
symptoms when AR symptoms flared up. Many (56%) avoided the outdoors during the allergy
season because of worsening asthma symptoms. Many (60%) indicated difficulty in effectively
treating both conditions, and 72% were concerned about using excessive medication. In general,
respondents from the Asia-Pacific region reported more disruption of activities caused by
symptoms and more concerns and difficulties with medications than did those from Europe.
Differences between the two regions in medication use included more common use of inhaled
corticosteroids in Europe and more common use of Chinese herbal remedies in the Asia-Pacific
region.
Conclusion: Results of this survey suggest that comorbid asthma and AR substantially impact
patient well-being and that the worsening of AR symptoms in patients with asthma can be
associated with worsening asthma symptoms. These findings underscore the need for physicians
who treat patients with asthma to evaluate treatment options for improving symptoms of both AR
and asthma when present concomitantly.
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Background
Asthma and allergic rhinitis (AR) are chronic inflamma-
tory conditions of the airways that affect a large propor-
tion of the general population [1,2]. These diseases are
often comorbid: 20–40% of patients with AR are reported
to have asthma, and 30–90% of patients with asthma
have AR [3-5]. AR is also a risk factor for developing
asthma [3], and a number of studies have shown that AR
usually precedes asthma in affected patients [6]. Moreo-
ver, the inflammatory mechanisms are similar in both
conditions [7].
In addition to the symptomatic burden of AR in patients
with asthma, comorbid AR may be associated with more
asthma-related healthcare resource use, including emer-
gency room visits and hospitalizations, and greater treat-
ment costs than for patients with asthma alone [6,8-10].
The associations between AR and asthma with regard to
epidemiology, to health-related outcomes, and to charac-
teristics of inflammation are reviewed in the subsequent
two papers in this supplement [11,12]. Our current
understanding of the shared pathophysiology, health
impairments, and socioeconomic costs of asthma and AR
has culminated in the Allergic Rhinitis and its Impact on
Asthma guidelines, which recommend a therapeutic 'one
airway' approach that combines treatment of both upper
and lower airways [2,3,13].
While there are several surveys assessing patient perspec-
tives on asthma and on AR [14,15], relatively few have
focused on the healthcare concerns and issues faced by
patients burdened with both diseases [16]. The aim of this
international survey of adult and pediatric patients in
eight countries in Europe and Asia was to understand how
and when the diagnoses of asthma and AR were made, to
understand the most frequent and bothersome symptoms
associated with asthma and AR, to understand medica-
tions used and attitudes toward such medications, and to
understand the impact of comorbid asthma and AR on
patient well-being.
Methods
Adult patients 18–64 years of age and parents of patients
6–18 years of age were recruited for the study from four
countries in the Asia-Pacific region (China, Singapore,
South Korea, and Taiwan) and from four countries in
Europe (France, Germany, Italy, and the United King-
dom). Households were randomly called, and potential
respondents were screened to ensure recruitment of an
equal number of adult patients and parents of pediatric
patients with concomitant asthma and symptoms sugges-
tive of AR. Potential respondents in the Asia-Pacific coun-
tries were also referred by other patients or intercepted at
clinics, hospitals, and pharmacies and were interviewed
face to face. A prior diagnosis of asthma and the presence
of AR were self-reported by patients. AR was defined as
congestion, sneezing, runny or itchy nose, and red,
watery, itchy eyes.
The survey was conducted by an international research
firm, which coordinated the translation of questions into
the language of each country and collected and summa-
rized the survey results. Telephone interviews lasted up to
15 minutes. Survey questions were not validated. The sur-
vey comprised 21 questions, some with multiple parts,
investigating the onset and nature of allergic and asth-
matic symptoms, the extent to which daily activities and
sleep were affected by these symptoms, the types of allergy
and asthma therapies, and the attitudes about these ther-
apies.
Results
Study population
Survey participants included 809 patients from four coun-
tries in Europe and 810 patients from four countries in the
Asia-Pacific region (Table 1). The average age of children
was 11 years; 59% were male. The average age of adult
patients was 40 years; 43% were male.
Diagnosis
More than two-thirds of patients were already experienc-
ing symptoms of AR at the time their asthma was diag-
nosed (Table 2). For a majority of patients (85%), the
diagnosis of AR had been made by a healthcare provider,
including a physician (81%), a Chinese herbalist (3%), or
a pharmacist (1%). In the United Kingdom, the frequency
of AR diagnosis was lower than in other countries: only
60% of patients reported a diagnosis of AR although they
all reported symptoms of AR.
Symptoms
A majority of patients (86% of adults and 88% of chil-
dren) had experienced ≥5 symptoms identified in the sur-
vey. When the diagnosis of asthma was made at an earlier
age (mean age 12.1 years), patients reported ≥9 symptoms
of asthma and AR. By contrast, when the diagnosis was
made later (age 15.6 years), patients reported fewer symp-
toms (≤5).
Overall, 73% of adults and 76% of children experienced
cough at one time or another; 77% of adults and 81% of
children experienced wheeze; 80% of adults and 79% of
children experienced sneeze; 75% of adults and 79% of
children experienced stuffy or blocked nose or nasal con-
gestion; 77% of adults and 76% of children experienced a
runny nose; 70% of adults and 72% of children experi-
enced an itchy nose; and 61% of adults and 62% of chil-
dren experienced red, watery, itchy, or puffy eyes.BMC Pulmonary Medicine 2006, 6(Suppl 1):S3
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The most frequently experienced symptoms and the most
troublesome symptoms are presented by region and by
age group in Table 3. In the Asia-Pacific region, almost
one-half of patients (47%) experienced symptoms only
during the allergy season. In the European region, 32%
experienced symptoms only during the allergy season
while 39% experienced symptoms throughout the year
but more so during the allergy season (Table 3).
Link between allergy and asthma
Almost two-thirds of patients (64%) believed that people
with AR were, in general, also likely to have asthma. This
was supported by the fact that a majority (69% of adults
and 76% of children) had pre-existing symptoms of AR
when asthma was first diagnosed. In this subgroup of
patients with AR, however, only 43% had concerns (ver-
sus 51% with no concerns) about developing asthma
before the diagnosis, although more parents were con-
cerned about their children than adults were about them-
selves (55% versus 31%; P ≤ 0.05).
Asthma and allergy treatments
The proportions of patients using asthma medications
were significantly different (P ≤ 0.05) between the Euro-
pean and Asia-Pacific regions for each category of asthma
medication except leukotriene receptor antagonists,
which were used by 3% of patients in each region (Figure
1). Short-acting β2-agonists were the most commonly
used medications for asthma (38% of patients overall). A
majority of patients on asthma medications (84% of
adults and 85% of children) reported that they were very
or fairly satisfied with their asthma treatment. Fewer par-
ents of children than adults (77% versus 93%, P ≤ 0.05)
were very satisfied or fairly satisfied with inhaled corticos-
teroids or long-acting β-agonists.
The percentages of patients using most categories of
allergy medications were significantly different (P ≤ 0.05)
between the European and Asia-Pacific regions; antihista-
mines and nasal corticosteroids were used by more (P ≤
0.05) patients in Europe than in the Asia-Pacific region
Table 2: Diagnosis of asthma and allergic rhinitis (AR)
Europe (n = 809) Asia-Pacific region (n = 810) Adults (n = 813) Children (n = 806)
Mean age (years) when asthma was diagnosed 13.2 13.2 21.2* 5.1
Mean age (years) when AR was diagnosed 13.5 13.3 21.7* 5.5
Percentage of patients already experiencing AR 
symptoms at the time of diagnosis of asthma
69* 77 69* 76
Percentage of patients who had diagnosis of AR
By a physician 84* 78 77* 84
By a pharmacist 1 2 1 1
By a Chinese herbalist 0* 6 4 2
Not diagnosed by healthcare provider 15 15 18* 13
*Significant (P ≤ 0.05) difference between Europe and the Asia-Pacific region or between adults and children.
Table 1: Study populations
Country and region Number of adults Number of children Total
Total 18–34 yearsa 35 to ≥65 yearsb Total 6–14 years 15–18 yearsa
Europe
France 102 39 63 100 59 41 202
Germany 102 40 62 100 80 20 202
Italy 104 45 59 100 70 30 204
United Kingdom 101 32 69 100 70 30 201
Total 409 156 253 400 279 121 809
Asia-Pacific
China 100 73 60 100 74 26 200
Singapore 100 40 27 100 79 21 200
South Korea 100 11 89 100 91 8 200
Taiwan 104 44 60 106 94 12 210
Total 404 168 236 406 338 68 810
Global total 813 324 489 806 617 189 1619
aBecause of the way the questions were asked, 18-year-old patients (20 in Europe, one in Asia-Pacific) could have been included in either the adult 
or the pediatric populations.
bThe only patients ≥65 were from South Korea (n = 17).BMC Pulmonary Medicine 2006, 6(Suppl 1):S3
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(Figure 2). Adults were less likely (P ≤ 0.05) than children
to use medications for their AR (77% versus 85%).
Among those who used corticosteroids for their AR, 73%
of adults and 80% of children were satisfied (very satisfied
or fairly satisfied) with the treatment. Among antihista-
mine users, 77% of adults and 84% of children were sat-
isfied.
Nevertheless, many patients (81% of adults and 82% of
parents of children) were very interested or fairly inter-
ested in a single medication for treating both asthma and
AR. The major reasons described by patients for this inter-
est were as follows (with some overlapping values): 'easier
to use' (36%), 'convenient' (26%), 'one tablet covers eve-
rything' (25%), 'less medication' (24%), and 'fewer side
effects' (5%).
Attitudes toward treatments
Attitudes about medications for asthma and AR are sum-
marized in Table 4 by region and by age category. The per-
centages of patients agreeing with each survey question
were significantly different between the European and
Asia-Pacific regions, with typically greater percentages of
patients in the Asia-Pacific region expressing difficulties or
concerns about medications (see Table 4).
Overall, most patients (75%) agreed that asthma and AR
bothered them in their day-to-day life. Moreover, most
patients (60%) agreed that it was difficult to effectively
treat both asthma and allergy at the same time and were
concerned about using too much medication for both
asthma and allergies (72%; see Table 4). Over three-quar-
ters of patients were concerned, strongly or to some
extent, about the potential side effects of corticosteroids
(81% of adults and 88% of parents of children) for treat-
ing asthma and AR; these concerns were expressed regard-
less of whether patients were or were not already receiving
corticosteroids (85% versus 84%, respectively) for one or
both diseases. Sixty-four percent of adults and 67% of par-
ents were concerned that their allergy medicine might
make them or their children drowsy. Most patients agreed
strongly or to some extent that they found it inconvenient
to take different medications for concomitant asthma and
allergy (63%), that nasal sprays were uncomfortable and/
or unpleasant (58%), and that an oral medication was
preferable to a nasal spray (60%) (see Table 4).
Impact on well-being
A majority of patients reported disruptions in their sleep
or daily activities ('a great deal,' 'quite a lot,' or 'a little bit')
as a result of asthma and AR (Figure 3). Patients in the
Asia-Pacific region reported most types of disruption sig-
nificantly more commonly (P ≤ 0.05) than those in the
European region (Figure 3).
Among the overall survey population, comorbid asthma
and AR disrupted the ability to get a good night's sleep
(79%), to concentrate at work and school (71%), to par-
ticipate in leisure and sports (75%), and to enjoy social
activities (54%). Even among those reporting satisfaction
('a great deal,' 'quite a bit,' or 'a little bit') with their treat-
ment for asthma, 52–78% reported an impairment in
their well-being, with most (78%) reporting disruption in
their ability to get a good night's sleep. Similarly, among
those expressing satisfaction with their treatment for AR,
54–80% reported impairments, with most (80%) report-
ing disruption in their ability to get a good night's sleep.
Among adults, 25–34% in each country believed that
Table 3: Most frequent or troublesome symptoms and their occurrence
Percentage of patients
Europe (n = 809) Asia-Pacific region (n = 810) Adults (n = 813) Children (n = 806)
Most frequently experienced symptoms
Stuffy, blocked nose or congestion 26* 47 34* 39
Sneezing 32* 47 38 42
Red, watery, itchy, or puffy eyes 37* 20 27 30
Coughing 23* 40 27* 37
Most troublesome symptoms
Stuffy, blocked nose or congestion 10 13* 13 12
Red, watery, itchy, or puffy eyes 16* 4 10 10
Wheezing 17 16 16 17
Shortness of breath 18 17 21* 15
Coughing 9* 19 11* 17
Extent and duration of symptoms
Just during allergy season 32* 47 40 39
Consistently throughout year 27* 23 27* 23
Throughout year, but more during season 39* 28 31* 36
*Significant (P ≤ 0.05) difference between Europe and the Asia-Pacific region or between adults and children.BMC Pulmonary Medicine 2006, 6(Suppl 1):S3
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Medications used for asthma Figure 1
Medications used for asthma. Medications used by region (a) and by age group (b). *P ≤ 0.05 for comparison between 
Europe and the Asia-Pacific region or between adults and children. SABA, short-acting β-agonist; LABA, long-acting β-agonist; 
ICS, inhaled corticosteroid; OCS, oral corticosteroids; LTRA, leukotriene receptor antagonist.
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Medications used for allergic rhinitis Figure 2
Medications used for allergic rhinitis. Medications used by region (a) and by age group (b). *P ≤ 0.05 for comparison 
between Europe and the Asia-Pacific region or between adults and children. CS, corticosteroid; LTRA, leukotriene receptor 
antagonist.
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asthma and AR were equally disruptive to their well-
being; parents of 30–35% of children believed the same.
By country within region, 28–29% of patients in the Euro-
pean countries and 27–39% of patients in the Asia-Pacific
region believed that asthma and AR were equally disrup-
tive to their well-being.
Most patients reported that the symptoms of AR affected
their asthma and their well-being during the allergy sea-
son all of the time, much of the time, or some of the time
(Figure 3). Fifty-six percent avoided the outdoors during
the allergy season because their asthma symptoms wors-
ened when they were outside; 76% reported that nasal
and chest symptoms developed with exposure to allergy
triggers; and 79% reported that when their allergies acted
up, their asthma symptoms became worse.
Discussion
The results of this survey highlight the limitations
imposed on daily life by the presence of comorbid asthma
and AR. Approximately 70% or more of all patients
reported a disruption in daily activities, including the abil-
ity to get a good night's sleep, to participate in leisure and
sports activities, and to concentrate at work or school.
More than one-half of patients reported that their symp-
toms had a negative affect on their ability to enjoy social
activities.
More than two-thirds of the patients included in this sur-
vey were already experiencing AR symptoms when the
diagnosis of asthma was made; this result reflects the
comorbid nature of these disorders. For three-quarters of
adult and pediatric patients, asthma symptoms increased
some to all of the time when symptoms of AR flared up;
similar numbers reported developing nasal and chest
symptoms when coming into contact with allergy triggers.
Interestingly, a recent small, prospective cohort study
found that patients with concomitant asthma and AR
experienced significantly worse physical functioning at
pollen peak than those with only AR [17]. In the present
study, over one-half of adult and pediatric patients
avoided the outdoors during the allergy season because of
fears that their asthma symptoms might worsen.
Some differences were seen between the two geographic
regions in the frequency of asthma and AR symptoms, the
bothersome nature of these symptoms, and the extent and
duration of symptoms. In particular, the disruption of
activities caused by symptoms was reported more com-
monly by respondents in the Asia-Pacific region than in
Europe. Seventy-one percent of Asian respondents
reported avoiding the outdoors during the allergy season
because of fears that their asthma symptoms might
worsen, while over 80% reported disruption of sleep, of
concentration at work or school, and of participation in
leisure or sports activities. Moreover, higher percentages
of respondents from the Asia-Pacific region than from
Europe reported concerns and difficulties with medica-
tions, including concerns about potential side effects of
corticosteroids and about using too much medication for
their asthma and allergies. Possible reasons for these dif-
ferences between the two geographic groups of respond-
ents could be cultural differences or differences between
the two regions in the environment, allergic triggers, or
treatments used.
Differences between the two regions were seen also in
medication use by patients. In Europe, most patients
received short-acting β2-agonists and inhaled corticoster-
oids for their asthma and received oral antihistamines for
Table 4: Attitudes of survey participants about asthma and allergic rhinitis medications
Attitude expressed Percentage of patients in agreement with survey questiona
Europe (n = 809) Asia-Pacific region (n = 810) Adults (n = 813) Children (n = 806)
Asthma and/or allergies interfere with day-to-day life 70* 80 74 76
Difficult to treat asthma and allergy conditions effectively 
at the same time
47* 73 58 62
Concerned about using too much medication for both 
asthma and allergies
59* 85 65* 79
Concerned about the potential side effects of using 
corticosteroids for asthma and allergies
76* 92 81* 88
Concerned that an allergy medication that might cause 
drowsiness
54* 77 64 67
Inconvenient to take different medications for asthma 
and allergy symptoms
47* 78 63 62
Nasal sprays uncomfortable/unpleasant to treat allergies 52* 65 57 59
Oral medication preferable over nasal spray for allergies 62* 57 60 60
*Significant (P ≤ 0.05) difference between Europe and the Asia-Pacific region or between adults and children.
aAgreement was defined as agree strongly or agree somewhat.BMC Pulmonary Medicine 2006, 6(Suppl 1):S3
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Impact on patient well-being Figure 3
Impact on patient well-being. Frequency of symptoms and disruption of sleep and activities caused by comorbid asthma 
and allergic rhinitis, by region (a) and by age group (b). *P ≤ 0.05 for comparison between Europe and the Asia-Pacific region or 
between adults and children. For symptoms, a positive response was defined as symptoms occurring all of the time, a lot of the 
time, or some of the time. Disruption was defined as occurring a great deal, quite a lot, or a little bit.
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AR. By contrast, patients in the Asia-Pacific region used
these treatments, particularly inhaled corticosteroids, less
frequently and instead relied more on Chinese herbal
remedies for both their asthma and their AR symptoms. It
has been recently reported that such nonconventional
treatments may have some benefit [18]. The methods
used to study complementary and alternative therapies in
rhinitis and asthma are poor, however, and in general
there is little proof of efficacy for such therapies in these
conditions [19].
It would have been interesting to know to what degree AR
in and of itself contributed to decreased well-being.
Among patients consulting with general practitioners for
their AR in one study, 40% of those with mild rhinitis and
>80% of those with moderate/severe rhinitis reported
impaired activities, including impaired quality of life,
sleep, daily activities, and work performance [20]. Distin-
guishing the relative contributions of asthma and AR to
decreased well-being in the present survey would have
been difficult, however – in part because all patients in the
study had both conditions.
An inability to treat both asthma and AR together was a
concern of respondents to the survey: approximately 60%
of patients in each age group found it difficult to treat
both conditions effectively at the same time. Moreover,
two-thirds of adult patients and three-quarters of parents
of pediatric patients were concerned about using too
much medication to treat the two conditions.
The route of administration was an important considera-
tion among survey respondents. Nearly 60% of all
patients reported that they found nasal sprays uncomfort-
able or unpleasant for treating AR; and over one-half of all
patients reported that they preferred using an oral medica-
tion to nasal sprays for treating these symptoms.
Patients' negative perceptions about side effects were also
highlighted in the survey. Most respondents were con-
cerned about the potential side effects of using corticoster-
oids for treating asthma or AR, and a majority of adult
patients and parents were concerned that the allergy med-
icine might make them or their children drowsy.
A limitation of this survey is that participants were identi-
fied according to self-reports of asthma and symptoms of
AR. Moreover, the survey questionnaire was not a vali-
dated instrument. In addition, patients' and parents'
answers to questions about the impact of asthma and AR
on well-being could be subject to recall bias.
A strength of this study is the large sample size (800
patients in Europe and 800 in the Asia-Pacific region). The
representativeness and comparability of the two groups of
participants is not certain, however, because survey partic-
ipation in Europe was limited to individuals with a tele-
phone in the household, whereas in Asia-Pacific countries
some patients were recruited by other patients or at clin-
ics. A combination of telephone and door-to-door surveys
has been used by other surveys to evaluate asthma, includ-
ing the Asthma Insights and Reality study [21].
Conclusion
As highlighted by the Allergic Rhinitis and its Impact on
Asthma guidelines [2], asthma and AR are related condi-
tions and should be considered together when treatment
options are discussed with patients. The results of this sur-
vey suggest that the worsening of AR symptoms in
patients with asthma can be associated with worsening
asthma symptoms, and that comorbid asthma and AR can
cause substantial disruption in daily activities. Moreover,
study respondents expressed concerns and difficulties
with medications to treat asthma and AR.
AR and asthma are most commonly managed in the pri-
mary care setting. Physicians treating patients with asthma
or AR must remain vigilant to the possible presence of the
other condition, be aware of the risks posed by one condi-
tion to the development of the other, and evaluate treat-
ment options for improving symptoms of both
conditions when present concomitantly. In addition, phy-
sicians must be aware of possible patient concerns about
medications, particularly patient concerns about potential
side effects of corticosteroids and about using too much
medication for their asthma and allergies. More generally,
there is a need to promote the use of combined therapies
that are safe and effective for treating symptoms of both
asthma and AR, and that address the inflammatory nature
of these two conditions affecting the 'one airway.'
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